Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2018.03.518 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimal ablation pattern on Intraprocedural echocardiography is associated with favorable clinical outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
J Cardiol
January 2025
Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.
Background: Alcohol septal ablation (ASA) is used to treat drug-refractory hypertrophic obstructive cardiomyopathy (HOCM). Intraprocedural echocardiography is essential for identifying the septal area perfused by each septal branch; however, its role in determining the procedural endpoint of ASA remains unclear. This retrospective study aimed to evaluate the impact of intraprocedural echocardiographic findings on clinical outcomes and left ventricular pressure gradient (LVPG) after ASA.
View Article and Find Full Text PDFAssociation with Outcome of the Regurgitant-Volume Adjusted Right Ventricular Ejection Fraction in Secondary Tricuspid Regurgitation.
J Am Soc Echocardiogr
January 2025
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; Department of Cardiology, Istituto Auxologico Italiano, IRCCS, Milan, Italy.
Background: In patients with secondary tricuspid regurgitation (STR), right ventricular ejection fraction (RVEF) may not accurately reflect the actual RV systolic performance since a considerable amount of the RV stroke volume (SV) is regurgitated back into the right atrium. To overcome this limitation, we explored the association with the outcome of the effective RVEF (eRVEF), which accounts for the tricuspid regurgitant volume (RegVol).
Methods: 513 patients with STR (mean age 75±13 years, 39% atrial STR, 58% severe) underwent complete two-, three-dimensional, and Doppler echocardiography.
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.
Lancet Diabetes Endocrinol
January 2025
Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. Electronic address:
Background: About half of patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) have type 2 diabetes. In the STEP-HFpEF DM trial of adults with obesity-related HFpEF and type 2 diabetes, subcutaneous once weekly semaglutide 2·4 mg conferred improvements in heart failure-related symptoms and physical limitations, bodyweight, and other heart failure outcomes. We aimed to determine whether these effects of semaglutide differ according to baseline HbA.
View Article and Find Full Text PDFExploring chitin metabolite profiles and sensitivity differences in Collembola species exposed to teflubenzuron.
Ecotoxicol Environ Saf
January 2025
Amsterdam Institute for Life and Environment (A-LIFE), Vrije Universiteit Amsterdam, De Boelelaan 1108, Amsterdam 1081Hz, the Netherlands. Electronic address:
Effective environmental risk assessments of chemical plant protection products, such as benzoylurea pesticides, are crucial for safeguarding ecosystems. These pesticides, including teflubenzuron, target chitin synthesis in arthropods but also pose risks to non-target soil fauna like Collembola, which play essential roles in decomposition and nutrient cycling. This study combines traditional toxicity tests with a metabolomic approach to examine the interspecies specific sensitivity of three Collembola species - Sinella curviseta, Ceratophysella denticulata, and Folsomia candida - to teflubenzuron.
View Article and Find Full Text PDFOrismilast, a PDE4B/D inhibitor, in moderate-to-severe atopic dermatitis: Efficacy and safety from a multicenter, randomized, placebo-controlled, phase 2b dose-ranging study (ADESOS).
Br J Dermatol
January 2025
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, characterized by eczematous skin lesions and pruritus. There is an unmet need for effective first-line systemic therapies with good safety profiles, particularly oral medications. Orismilast is a novel first-in-class oral phosphodiesterase-4 (PDE4) B/D inhibitor under investigation for the treatment of moderate-to-severe AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!